-
公开(公告)号:US20230316530A1
公开(公告)日:2023-10-05
申请号:US18127991
申请日:2023-03-29
Applicant: EXINI Diagnostics AB
Inventor: Jens Filip Andreas Richter , Kerstin Elsa Maria Johnsson , Erik Konrad Gjertsson , Aseem Undvall Anand
IPC: G06T7/11 , G16H50/50 , G16H30/20 , G16H50/30 , G16H50/20 , G16H30/40 , A61B6/03 , A61B6/00 , A61K51/04 , G06V20/64 , G06V20/69 , G06V30/24 , G06F18/214
CPC classification number: G06T7/11 , G16H50/50 , G16H30/20 , G16H50/30 , G16H50/20 , G16H30/40 , A61B6/032 , A61B6/037 , A61B6/463 , A61B6/466 , A61B6/481 , A61B6/505 , A61B6/507 , A61B6/5205 , A61B6/5241 , A61B6/5247 , A61K51/0455 , G06V20/64 , G06V20/695 , G06V20/698 , G06V30/2504 , G06F18/214 , G06V2201/031 , G06V2201/033
Abstract: Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific anatomical regions (e.g., organs and/or tissue). Notably, the image analysis approaches described herein are not limited to a single particular organ or portion of the body. Instead, they are robust and widely applicable, providing for consistent, efficient, and accurate detection of anatomical regions, including soft tissue organs, in the entire body. In certain embodiments, the accurate identification of one or more such volumes is used to automatically determine quantitative metrics that represent uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.
-
公开(公告)号:US11657508B2
公开(公告)日:2023-05-23
申请号:US16734599
申请日:2020-01-06
Applicant: EXINI Diagnostics AB
Inventor: Jens Filip Andreas Richter , Kerstin Elsa Maria Johnsson , Erik Konrad Gjertsson , Aseem Undvall Anand
IPC: G06T7/00 , G06T7/11 , G16H50/50 , G16H30/20 , G16H50/30 , G16H50/20 , G16H30/40 , A61B6/03 , A61B6/00 , A61K51/04 , G06V20/64 , G06V20/69 , G06V30/24 , G06F18/214
CPC classification number: G06T7/11 , A61B6/032 , A61B6/037 , A61B6/463 , A61B6/466 , A61B6/481 , A61B6/505 , A61B6/507 , A61B6/5205 , A61B6/5241 , A61B6/5247 , A61K51/0455 , G06F18/214 , G06V20/64 , G06V20/695 , G06V20/698 , G06V30/2504 , G16H30/20 , G16H30/40 , G16H50/20 , G16H50/30 , G16H50/50 , G06V2201/031 , G06V2201/033
Abstract: Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific anatomical regions (e.g., organs and/or tissue). Notably, the image analysis approaches described herein are not limited to a single particular organ or portion of the body. Instead, they are robust and widely applicable, providing for consistent, efficient, and accurate detection of anatomical regions, including soft tissue organs, in the entire body. In certain embodiments, the accurate identification of one or more such volumes is used to automatically determine quantitative metrics that represent uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.
-
23.
公开(公告)号:US11564621B2
公开(公告)日:2023-01-31
申请号:US16734609
申请日:2020-01-06
Applicant: Progenics Pharmaceuticals, Inc. , EXINI Diagnostics AB
Abstract: Presented herein are systems and methods that provide for automated analysis of medical images to determine a predicted disease status (e.g., prostate cancer status) and/or a value corresponding to predicted risk of the disease status for a subject. The approaches described herein leverage artificial intelligence (AI) to analyze intensities of voxels in a functional image, such as a PET image, and determine a risk and/or likelihood that a subject's disease, e.g., cancer, is aggressive. The approaches described herein can provide predictions of whether a subject that presents a localized disease has and/or will develop aggressive disease, such as metastatic cancer. These predictions are generated in a fully automated fashion and can be used alone, or in combination with other cancer diagnostic metrics (e.g., to corroborate predictions and assessments or highlight potential errors). As such, they represent a valuable tool in support of improved cancer diagnosis and treatment.
-
24.
公开(公告)号:US11534125B2
公开(公告)日:2022-12-27
申请号:US16856120
申请日:2020-04-23
Applicant: Progenics Pharmaceuticals, Inc. , EXINI Diagnostics AB
Inventor: Karl Vilhelm Sjöstrand , Jens Filip Andreas Richter , Lars Edenbrandt
IPC: G06K9/00 , A61B6/00 , G06T7/11 , G06T7/73 , G16H70/60 , G16H15/00 , G16H30/20 , G16H50/30 , G16H50/70 , G16H50/20 , G16H30/40 , A61B6/03 , A61K51/04 , G06T7/00
Abstract: Presented herein are systems and methods that provide for improved computer aided display and analysis of nuclear medicine images. In particular, in certain embodiments, the systems and methods described herein provide improvements to several image processing steps used for automated analysis of bone scan images for assessing cancer status of a patient. For example, improved approaches for image segmentation, hotspot detection, automated classification of hotspots as representing metastases, and computation of risk indices such as bone scan index (BSI) values are provided.
-
25.
公开(公告)号:US20200342600A1
公开(公告)日:2020-10-29
申请号:US16959887
申请日:2019-01-07
Applicant: Progenics Pharmaceuticals, Inc. , EXINI Diagnostics AB
Inventor: Karl Vilhelm Sjöstrand , Jens Filip Andreas Richter , Kerstin Elsa Maria Johnsson , Erik Konrad Gjertsson
IPC: G06T7/00 , A61B6/00 , A61B6/03 , A61K51/08 , G06T15/08 , G06T7/62 , G06T11/00 , G06N3/04 , G06N3/08
Abstract: Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and/or tissue. In certain embodiments, the accurate identification of one or more such volumes can be used to determine quantitative metrics that measure uptake of radiopharmaceuticals in particular organs and/or tissue regions. These uptake metrics can be used to assess disease state in a subject, determine a prognosis for a subject, and/or determine efficacy of a treatment modality.
-
-
-
-